Biocept, Inc., a cancer diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC), and circulating tumor DNA (ctDNA) assays utilizing a standard blood sample, or ‘liquid biopsy’. The company’s breast, lung and gastric cancer assays provide information to oncologists and other physicians that enable them to select personalized treatment for their patients based on data on the characteristics of their patients’ tumors. The company’s current assays and its planned future assays focus on all the key solid tumor indications utilizing its Target-Selector offering for the biomarker analysis of CTCs and ctDNA from a standard blood sample. The Target-Selector offering is based on an internally developed and patented, microfluidics-based CTC capture and analysis platform, with enabling features that change how CTC testing could be used by clinicians by providing real-time biomarker detection and monitoring requiring only a standard blood sample. The company’s patent pending ctDNA technology enables mutation detection with sensitivity and specificity and is applicable to nucleic acid from CTCs or other sample types, such as blood plasma. The company is continuing to commercialize its Target-Selector assays for various solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), gastric cancer, colorectal cancer, prostate cancer, and melanoma. These assays utilize the company’s dual CTC and ctDNA technology platform and provide biomarker analysis from a standard blood sample. For lung cancer, the company also offers a resistance panel assay consisting of the biomarkers MET, HER2 (both of which it performs using its technology for CTCs) and T790M which is performed using ctDNA in plasma. These biomarkers are used by physicians to identify the mechanism causing disease progression for patients with NSCLC who are being treated with TKI therapy and therefore could qualify for inclusion in a clinical trial. The company offers and conducts its commercialized diagnostic assays and offers its clinical trial services at its CLIA-certified, CAP-accredited and state- licensed laboratory. The company’s current assays and its planned near-term cancer diagnostic assays and clinical trial services include: CTC and ctDNA Testing: The company’s current assays and its other planned cancer diagnostic assays are based on its Target-Selector technologies and is intended to be performed only in its clinical laboratory. After completing testing, the company or its partners provide its customers with a report that describes the results of the analyses performed, designed to help oncologists and other physicians make better decisions about the treatment of their patients. Clinical Trial Services: The company plans to utilize its clinical laboratory and translational research capabilities to provide clinical trial and research services to pharmaceutical and biopharmaceutical companies and clinical research organizations to focus on their clinical trials. Business Strategy The company plans to provide oncologists and other physicians with a straightforward means to profile and characterize their patients’ tumors on a real-time basis by analyzing CTCs and ctDNA found in standard blood draws. The company intends to develop and commercialize a portfolio of proprietary CTC and ctDNA assays and services, to enable physicians to develop personalized treatment plans; scale its internal sales and marketing capabilities; develop and expand its collaborations with leading university hospitals and research centers; improve its efforts in reaching and educating oncologists and other physicians about CTC and ctDNA assays; increase its efforts to provide biopharmaceutical companies and clinical research organizations with its current and planned CTC and ctDNA assays and services; conduct additional clinical studies of breast cancer, NSCLC and other CTC and ctDNA assays the company plans to introduce; and continue to improve its current and planned CTC and ctDNA assays and reduce the costs associated with providing them through internal research and development and partnering with major technology developers and reagent suppliers. Research and Development The company incurred research and development expenses of $2.9 million, as of December 31, 2015. Intellectual Property Patents: As of December 31, 2015, the company owned 10 issued U.S. patents, as well as pending U.S. patent applications and corresponding patents and patent applications internationally. In addition, as of December 31, 2015, the company co-owned two pending U.S. patent applications, as well as corresponding foreign patents and applications. Competition The company’s competitors include Atossa; Qiagen; Roche Molecular Systems, Inc.; Trovagene; Guardant; Janssen Diagnostoric; Alere (Adnagen); Illumina; Apocell; EPIC Sciences; Clearbridge Biomedics; Biodesix; Thermo-Fisher; Foundation Medicine; Neogenomics; Cynvenio Biosystems; Genomic Health; Fluxion Biosciences; RareCells; ScreenCell and Silicon Biosystems. History Biocept, Inc. was founded in 1997 in California.
biocept inc (BIOC:NASDAQ CM)
5810 Nancy Ridge Drive
San Diego, CA 92121
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|No competitor information is available for BIOC.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact BIOCEPT INC, please visit www.biocept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.